In 2025, the Indian animal health market stood at approximately 1.73 billion dollars. By 2033, it is projected to reach a staggering 4.17 billion dollars, growing at a compound annual growth rate of over 10 per cent. With the world’s largest livestock population of over 536 million animals, the third-largest pet population globally at 32 million and counting, and aggressive government disease eradication programs, the opportunity is nothing short of massive.
Yet, when one scans the headlines of India’s pharmaceutical industry, a curious omission emerges. The Indian pharma story of the past two decades, told through the rise of Sun Pharma, Cipla, Dr. Reddy’s, and Biocon, is almost exclusively a human health story. These giants have built empires in generics, biosimilars, and active pharmaceutical ingredients, serving patients from Boston to Brisbane.
Free Membership Required
You must be a Free member to access this content.
